Avatrombopag (Doptelet)

Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.

About Avatrombopag

What it is

Avatrombopag is a thrombopoietin receptor agonist: it mimics the hormone that tells the bone marrow to make platelets. It is used to raise the platelet count before a planned procedure in people with chronic liver disease, and for long-lasting immune thrombocytopenia (ITP). It is sold as Doptelet.

How genes come into it

The US FDA lists two kinds of genes for avatrombopag. Because raising platelets can add to the tendency to form clots, the label mentions inherited clotting conditions such as factor V Leiden (F5), the prothrombin 20210A variant (F2) and deficiencies of antithrombin, protein C and protein S. Separately, avatrombopag is broken down by CYP2C9 and CYP3A4, and people with low CYP2C9 activity have higher levels. There is no CPIC or DPWG guideline.

Published guidelines

Clinical guidelines that name a gene for Avatrombopag. They sort people into groups by the gene copies they carry.

US FDA: F2, F5, PROC, PROS1, SERPINC1. F2: rs1799963 G/Prothrombin 20210A, rs1799963 Prothrombin 20210A/Prothrombin 20210A · F5: rs6025 C/Factor V Leiden (T), rs6025 Factor V Leiden (T)/Factor V Leiden (T). 2021.

US FDA: CYP2C9. CYP2C9 activity score 0 to 1.5. Data that Demonstrate a Potential Impact on Pharmacokinetic Properties Only.

What research found

Every published finding on gene variants and Avatrombopag. Upload your DNA file to see which of these rows apply to you.

Metabolism (6 findings)

Studies of how quickly the body processes this medication.

ABCB1 rs1128503: Genotypes AA + AG is associated with increased exposure to avatrombopag in healthy individuals as compared to genotype GG.

CYP2C9 CYP2C9*1, CYP2C9*3: CYP2C9 *1/*3 (assigned as intermediate metabolizer phenotype) is associated with increased exposure to avatrombopag in healthy individuals as compared to CYP2C9 *1/*1.

CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3: CYP2C9 *1/*2 + *1/*3 (assigned as intermediate metabolizer phenotype) is associated with increased exposure to avatrombopag in healthy individuals as compared to CYP2C9 *1/*1 (assigned as normal metabolizer phenotype) .

CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3: CYP2C9 *1/*2 + *1/*3 (assigned as intermediate metabolizer phenotype) is not associated with increased response to avatrombopag in healthy individuals as compared to CYP2C9 *1/*1 (assigned as normal metabolizer phenotype) .

Response (2 findings)

Studies of how well it worked in people carrying a variant.

CTLA4 rs231775: Allele A is not associated with increased clinical benefit to avatrombopag, corticosteroids, eltrombopag or rituximab Thrombocytopenia as compared to allele G.

CTLA4 rs3087243: Allele G is not associated with increased clinical benefit to avatrombopag, corticosteroids, eltrombopag or rituximab Thrombocytopenia as compared to allele A.

Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.

Related Drugs

More drugs from the same category

Accupril (ACE Inhibitors)

ACE Inhibitors (class) (ACE Inhibitors)

Acenocoumarol (Anticoagulants)

Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.

Back to Medications

Content updated September 2026.

ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.

Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026

Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com